Information
401 Yangcheon-ro, Gangseo-gu, Seoul, South Korea
+82 2-6442-8345
-
-
Overview
- Summary
- PROTIA Inc. is a specialized in-vitro diagnostic medical device company dedicated to contributing to human welfare and health through disease prediction, early diagnosis, and the development of new pharmaceuticals. The company is a bio-venture possessing innovative biomarker development and substance analysis technologies essential for early diagnosis of intractable diseases. It engages in the development, production, and export of unique in-vitro diagnostic medical devices such as allergy diagnostic kits, immune antibody monitoring kits, and next-generation pregnancy diagnostic kits. PROTIA offers a diverse range of diagnostic product lines, including human and animal allergy diagnostics, point-of-care diagnostics, autoimmune diagnostics, and antibiotic susceptibility diagnostics. The company is continuously expanding its business scope through the development of early cancer diagnostic kits.PROTIA Inc. is a specialized in-vitro diagnostic medical device company dedicated to contributing to human welfare and health through disease prediction, early diagnosis, and the development of new pharmaceuticals. The company is a bio-venture possessing innovative biomarker development and substance analysis technologies essential for early diagnosis of intractable diseases. It engages in the development, production, and export of unique in-vitro diagnostic medical devices such as allergy diagnostic kits, immune antibody monitoring kits, and next-generation pregnancy diagnostic kits. PROTIA offers a diverse range of diagnostic product lines, including human and animal allergy diagnostics, point-of-care diagnostics, autoimmune diagnostics, and antibiotic susceptibility diagnostics. The company is continuously expanding its business scope through the development of early cancer diagnostic kits.
- Key Products/Technologies
- The allergy diagnostic product line includes PROTIA Allergy-Q 192D, a premium kit capable of diagnosing 176 types of allergy-causing substances in a single test. This product encompasses 118 naturally derived, 48 component allergens, and 10 drug/chemical allergens, making it the world's only multi-diagnostic kit capable of testing for drug and chemical substances. Various panels of allergy diagnostic kits, such as PROTIA Allergy-Q 128M, PROTIA Allergy-Q 96M, and PROTIA Allergy-Q 64D, are also provided. The inclusion of component allergens enables more accurate allergy diagnosis capabilities.The allergy diagnostic product line includes PROTIA Allergy-Q 192D, a premium kit capable of diagnosing 176 types of allergy-causing substances in a single test. This product encompasses 118 naturally derived, 48 component allergens, and 10 drug/chemical allergens, making it the world's only multi-diagnostic kit capable of testing for drug and chemical substances. Various panels of allergy diagnostic kits, such as PROTIA Allergy-Q 128M, PROTIA Allergy-Q 96M, and PROTIA Allergy-Q 64D, are also provided. The inclusion of component allergens enables more accurate allergy diagnosis capabilities.
- Among the immune diagnostic product line, ImmuneCheck IgG is the world's first point-of-care diagnostic kit for quantitative total IgG using whole blood. IMSAFE Saliva is the world's first non-invasive saliva-based product for quantitative measurement of immunoglobulin A (IgA) protein, allowing immune health status to be checked in 15 minutes with just a few drops of saliva. This product incorporates proprietary patented technology that enables users to visually confirm results without specialized equipment.Among the immune diagnostic product line, ImmuneCheck IgG is the world's first point-of-care diagnostic kit for quantitative total IgG using whole blood. IMSAFE Saliva is the world's first non-invasive saliva-based product for quantitative measurement of immunoglobulin A (IgA) protein, allowing immune health status to be checked in 15 minutes with just a few drops of saliva. This product incorporates proprietary patented technology that enables users to visually confirm results without specialized equipment.
- The antibiotic susceptibility diagnostic product line, PROTIA AST DL001 and Q-AST 192 Pro, are electronic devices for microbial antibiotic susceptibility testing utilizing capacitance sensor technology. This innovative technology enables simultaneous testing of 192 channels and is equipped with 37 types of antibiotics, drastically reducing the conventional 3-day testing time to within 24 hours. It provides high accuracy through real-time electrical signal measurement and pattern recognition algorithms.The antibiotic susceptibility diagnostic product line, PROTIA AST DL001 and Q-AST 192 Pro, are electronic devices for microbial antibiotic susceptibility testing utilizing capacitance sensor technology. This innovative technology enables simultaneous testing of 192 channels and is equipped with 37 types of antibiotics, drastically reducing the conventional 3-day testing time to within 24 hours. It provides high accuracy through real-time electrical signal measurement and pattern recognition algorithms.
- The animal diagnostic product line includes ANITIA Canine IgE for dog allergy diagnosis, ANITIA Feline IgE I for cat allergy multi-diagnosis, and ANITIA Equine IgE I, II for horse allergy diagnosis, among other diverse animal allergy diagnostic products. Animal food intolerance diagnostic products, such as ANITIA Canine Food Intolerance Test 128, are also part of the portfolio.The animal diagnostic product line includes ANITIA Canine IgE for dog allergy diagnosis, ANITIA Feline IgE I for cat allergy multi-diagnosis, and ANITIA Equine IgE I, II for horse allergy diagnosis, among other diverse animal allergy diagnostic products. Animal food intolerance diagnostic products, such as ANITIA Canine Food Intolerance Test 128, are also part of the portfolio.
- The autoimmune disease diagnostic product line, PROTIA ANA Profile, uses a line blot method to simultaneously test for 18 types of systemic autoantibodies from minimal serum or plasma samples. It offers higher sensitivity, specificity, and cost-effectiveness compared to conventional testing methods.The autoimmune disease diagnostic product line, PROTIA ANA Profile, uses a line blot method to simultaneously test for 18 types of systemic autoantibodies from minimal serum or plasma samples. It offers higher sensitivity, specificity, and cost-effectiveness compared to conventional testing methods.
- Key core technologies include multi-diagnostic methods based on parallel line array (PLA) technology and line blot technology. Component-resolved diagnostics (CRD) detection technology enables precise allergen unit diagnosis. The company also possesses capabilities in biomarker development and protein analysis services.Key core technologies include multi-diagnostic methods based on parallel line array (PLA) technology and line blot technology. Component-resolved diagnostics (CRD) detection technology enables precise allergen unit diagnosis. The company also possesses capabilities in biomarker development and protein analysis services.
- Core Advantages
- Unrivaled multi-diagnostic technology capable of simultaneously diagnosing up to 192 types of allergy-causing antigens in a single test, representing a world-leading technological capability. This significantly surpasses the simultaneous antigen testing capacity of existing foreign products (1 to 30 types), establishing a distinct competitive advantage.Unrivaled multi-diagnostic technology capable of simultaneously diagnosing up to 192 types of allergy-causing antigens in a single test, representing a world-leading technological capability. This significantly surpasses the simultaneous antigen testing capacity of existing foreign products (1 to 30 types), establishing a distinct competitive advantage.
- Innovative diagnostic platform development capabilities, including the development of the world's first multi-diagnostic kit capable of testing for drug and chemical allergens. Commercialization of the world's first antibiotic susceptibility diagnostic product incorporating capacitance measurement technology. Launch of 'IMSAFE Saliva,' the world's first non-invasive saliva-based immune diagnostic product.Innovative diagnostic platform development capabilities, including the development of the world's first multi-diagnostic kit capable of testing for drug and chemical allergens. Commercialization of the world's first antibiotic susceptibility diagnostic product incorporating capacitance measurement technology. Launch of 'IMSAFE Saliva,' the world's first non-invasive saliva-based immune diagnostic product.
- Provision of rapid and precise diagnostic results, with the capacitance sensor technology significantly reducing antibiotic susceptibility testing time from 3 days to within 24 hours. The saliva-based immune diagnostic kit offers rapid results, allowing immune health status to be checked within 15 minutes. High-precision diagnostic capabilities are based on line blot technology.Provision of rapid and precise diagnostic results, with the capacitance sensor technology significantly reducing antibiotic susceptibility testing time from 3 days to within 24 hours. The saliva-based immune diagnostic kit offers rapid results, allowing immune health status to be checked within 15 minutes. High-precision diagnostic capabilities are based on line blot technology.
- A broad product portfolio and market expandability, encompassing diverse in-vitro diagnostic product lines such as human allergy, animal allergy, autoimmune diseases, antibiotic susceptibility, point-of-care diagnostics, and cancer diagnostics. This strength allows the company to address the demands of various domestic and international medical and veterinary markets.A broad product portfolio and market expandability, encompassing diverse in-vitro diagnostic product lines such as human allergy, animal allergy, autoimmune diseases, antibiotic susceptibility, point-of-care diagnostics, and cancer diagnostics. This strength allows the company to address the demands of various domestic and international medical and veterinary markets.
- Recognition of credible technology and quality through numerous prestigious awards and certifications, including the Jang Young-shil Award, World-Class Product designation, Korea Technology Award, and New Excellent Technology (NET) certifications. Acquisition of CE-IVDR certification further establishes a foundation for entry into the European market.Recognition of credible technology and quality through numerous prestigious awards and certifications, including the Jang Young-shil Award, World-Class Product designation, Korea Technology Award, and New Excellent Technology (NET) certifications. Acquisition of CE-IVDR certification further establishes a foundation for entry into the European market.
- Continuous research and development and a collaborative network, demonstrating ongoing investment in biomarker development and substance analysis technologies for early diagnosis of intractable diseases. Efforts to pioneer new markets are evident through the signing of an MOU with Yonsei University College of Medicine's faculty startup, Barabio, for joint R&D of chronic metabolic disease diagnostic products.Continuous research and development and a collaborative network, demonstrating ongoing investment in biomarker development and substance analysis technologies for early diagnosis of intractable diseases. Efforts to pioneer new markets are evident through the signing of an MOU with Yonsei University College of Medicine's faculty startup, Barabio, for joint R&D of chronic metabolic disease diagnostic products.
- Target Industrie
- Medical and healthcare industry sectors for disease prediction, early diagnosis, prevention, and treatment monitoring.Medical and healthcare industry sectors for disease prediction, early diagnosis, prevention, and treatment monitoring.
- Veterinary and pet industry sectors for animal allergy diagnosis, food intolerance diagnosis, and immune health management.Veterinary and pet industry sectors for animal allergy diagnosis, food intolerance diagnosis, and immune health management.
- Pharmaceutical and bio R&D industry sectors for new drug candidate verification, disease mechanism analysis, and early-stage clinical development verification.Pharmaceutical and bio R&D industry sectors for new drug candidate verification, disease mechanism analysis, and early-stage clinical development verification.
- Personal health management and wellness market for non-invasive immune health status monitoring.Personal health management and wellness market for non-invasive immune health status monitoring.
- Major Markets
- African regionAfrican region
- Russia, Malaysia, Vietnam, India, Middle East, China, Japan, Saudi Arabia, TaiwanRussia, Malaysia, Vietnam, India, Middle East, China, Japan, Saudi Arabia, Taiwan
- EuropeEurope
- United States, CanadaUnited States, Canada
- Brazil, MexicoBrazil, Mexico
- Certifications/Patents
- Key awards and certifications include the Jang Young-shil Award for 'AniCheck Bovine IgG' in 2024. Acquisition of World-Class Product certification in 2023. Recipient of the Korea Technology Award in 2016. Winner of the Regulatory Sandbox Challenge Grand Prize in 2021. Listed as an Excellent Company by the Korea Institute of Industrial Technology Evaluation and Management. Newly certified as an Innovative Medical Device Company in 2023. Selected as a Global Hidden Champion 1000+ company in 2024. Awarded the '3 Million Dollar Export Tower' on Trade Day in 2023.Key awards and certifications include the Jang Young-shil Award for 'AniCheck Bovine IgG' in 2024. Acquisition of World-Class Product certification in 2023. Recipient of the Korea Technology Award in 2016. Winner of the Regulatory Sandbox Challenge Grand Prize in 2021. Listed as an Excellent Company by the Korea Institute of Industrial Technology Evaluation and Management. Newly certified as an Innovative Medical Device Company in 2023. Selected as a Global Hidden Champion 1000+ company in 2024. Awarded the '3 Million Dollar Export Tower' on Trade Day in 2023.
- Technology certifications include NET (New Excellent Technology) for canine allergy 2-line multi-diagnosis technology. NET (New Excellent Technology) for rapid antibiotic susceptibility testing technology using capacitance measurement. CE-IVDR certification for allergy diagnostic kit testing equipment Q-Smart, Q-Station, and Q-Processor.Technology certifications include NET (New Excellent Technology) for canine allergy 2-line multi-diagnosis technology. NET (New Excellent Technology) for rapid antibiotic susceptibility testing technology using capacitance measurement. CE-IVDR certification for allergy diagnostic kit testing equipment Q-Smart, Q-Station, and Q-Processor.
- Patents include the registration of a patent for an electronic device and method for performing microbial antibiotic susceptibility testing using capacitance sensors. Domestic patent registration for a rapid diagnostic kit for illegal whale poaching in June 2025. Numerous patent applications and registrations related to specific proteins. Proprietary patented technology applied to the non-invasive immune diagnostic product 'IMSAFE Saliva'.Patents include the registration of a patent for an electronic device and method for performing microbial antibiotic susceptibility testing using capacitance sensors. Domestic patent registration for a rapid diagnostic kit for illegal whale poaching in June 2025. Numerous patent applications and registrations related to specific proteins. Proprietary patented technology applied to the non-invasive immune diagnostic product 'IMSAFE Saliva'.
Introduction
Location
401 Yangcheon-ro, Gangseo-gu, Seoul, South Korea
클릭하여 위치 살펴보기
